FDA Published Drug-Drug Interaction Assessment for Therapeutic Proteins Guidance for Industry

FDA published guidance to help sponsors of Investigational New Drug (IND) applications and applicants of Biologic License Applications (BLAs) determine the need for drug-drug interaction (DDI) studies for a therapeutic protein.